Bronchopulmonary Dysplasia: Then, Now, and Next.

Pediatr Allergy Immunol Pulmonol

Center for Excellence in Pulmonary Biology, Division of Pediatric Pulmonary, Asthma and Sleep Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, California, USA.

Published: September 2020

AI Article Synopsis

  • - Bronchopulmonary dysplasia (BPD) has seen significant changes in its definition and understanding over the past 50 years, influenced by advances in clinical care and the increasing survival rates of very preterm infants.
  • - Despite improved perinatal care, the incidence of BPD is on the rise, with a focus now on the role of antenatal risk factors and evolving strategies to prevent neonatal lung injury.
  • - An interdisciplinary approach to caring for infants with BPD, emphasizing growth and neurocognitive development, shows promise, with current data suggesting that many affected children have a quality of life similar to that of other preterm infants.

Article Abstract

Bronchopulmonary dysplasia (BPD) has evolved considerably since its first description over 50 years ago. This review aims to provide a historical framework for conceptualizing BPD and a current understanding of the changing definition, epidemiology, pathophysiology, treatment, and outcomes of BPD. The transdisciplinary approach that led to the initial phenotypic description of BPD continues to hold promise today. Investigators are refining the definition of BPD in light of changes in clinical care and increasing survival rates of very preterm infants. Despite improvements in perinatal care the incidence of BPD continues to increase. There is growing recognition that antenatal risk factors play a key role in the development of BPD. Strategies designed to prevent or limit neonatal lung injury continue to evolve. Defining the phenotype of infants with BPD can meaningfully direct treatment. Infants with BPD benefit from an interdisciplinary approach to longitudinal care with a focus on growth and neurocognitive development. While the ultimate impact of BPD on long-term pulmonary morbidity remains an active area of investigation, current data indicate that most children and adolescents with a history of BPD have a quality of life comparable to that of other preterm infants.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354034PMC
http://dx.doi.org/10.1089/ped.2020.1205DOI Listing

Publication Analysis

Top Keywords

bpd
11
bronchopulmonary dysplasia
8
bpd continues
8
preterm infants
8
infants bpd
8
dysplasia bronchopulmonary
4
dysplasia bpd
4
bpd evolved
4
evolved considerably
4
considerably description
4

Similar Publications

Background: Melanoma is the most aggressive and lethal skin cancer that affects thousands of people worldwide. Ruthenium complexes have shown promising results as cancer chemotherapeutics, offering several advantages over platinum drugs, such as potent efficacy, low toxicity, and less drug resistance. Additionally, anthraquinone derivatives have broad therapeutic applications, including melanoma.

View Article and Find Full Text PDF

Disrupted neonatal lung alveologenesis often leads to bronchopulmonary dysplasia (BPD), the most common chronic lung disease in children. The inhibition of type 2 alveolar (AT2) cell proliferation plays an important role in the arrest of alveologenesis. However, the mechanism of AT2 cell proliferation retardation in BPD is still not fully elucidated.

View Article and Find Full Text PDF

L-citrulline (L-CIT), a precursor to L-arginine (L-ARG), is a key contributor to the nitric oxide (NO) signaling pathway. Endothelial dysfunction, characterized by deficient nitric oxide synthesis, is implicated in the pathogenesis of various neonatal conditions such as necrotizing enterocolitis (NEC) and bronchopulmonary dysplasia (BPD) associated pulmonary hypertension (PH). This review summarizes the current evidence around the possible role of L-CIT supplementation in the treatment of these conditions.

View Article and Find Full Text PDF

Background: Bronchopulmonary dysplasia (BPD) is a chronic lung condition of premature neonates, yet without an established pharmacological treatment. The BPD rabbit model exposed to 95% oxygen has been used in recent years for drug testing. However, the toxicity of the strong hyperoxic hit precludes a longer-term follow-up due to high mortality after the first week of life.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!